Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-024-03905-0 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuantai Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local, B7-H1 Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, China.
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China.
- Department of Intensive Care Medicine, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chengdu, Sichuan, China.
- Division of Head & Neck Tumor Multimodality Treatment, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, China. aiping00222@163.com.
- Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China. huaxichenye@163.com.
Zitieren
APA
Li, Y., Min, Y., Wei, Z., Liu, Z., Pei, Y., Yang, Y., Gao, K., Song, G., Xu, S., He, S., Ge, J., Qing, Y., Wei, Y., Ai, P., Chen, Y., & Peng, X. (2025). Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03905-0
Vancouver
Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y, et al. Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167). Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03905-0
BibTeX
@article{Li2025,
author = {Li, Yuantai and Min, Yu and Wei, Zhigong and Liu, Zheran and Pei, Yiyan and Yang, Yujie and Gao, Kun and Song, Ge and Xu, Shihong and He, Shuangshuang and Ge, Junyou and Qing, Yan and Wei, Youneng and Ai, Ping and Chen, Ye and Peng, Xingchen},
title = {Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-024-03905-0}
}
EUVIMED